But instead of retreating, Empower and other compounding pharmacies are using a legal loophole that allows "customized" versions of the drugs, offering alternatives as low as $8 per month, compared to $500 to over $1,000 for brand-name versions
Talk with your own clinician before starting a GLP-1, especially if you are managing menopause symptoms, thyroid conditions, or anything else
The case is part of the Ozempic lawsuit currently pending in federal court in Pennsylvania
The HPA axis is the system responsible for helping regulate our bodys stress response
The 2026 ADA Standards of Care, released at the meeting, formally elevated cardiovascular and kidney risk reduction to a co-primary treatment goal alongside blood sugar control ending decades of practice in which A1C was the dominant benchmark
No peer-reviewed work covers co-administration with semaglutide, tirzepatide, or other incretin agonists [2][3]